Testing menstrual blood for human papillomavirus (HPV) could be a "robust alternative or replacement" for current cervical ...

Today, Hims & Hers Health, Inc. (NYSE: HIMS), the leading digital health and wellness platform, launched access to the Hims & ...

About 70 per cent of cases are prevented through cervical screening, according to cancer research, and the HPV vaccine is ...

Hims & Hers is moving beyond prescriptions to preventative testing.

A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need ...

The FDA has expanded the approval of Hologic’s Aptima human papillomavirus (HPV) assay for clinician-collected primary ...

Despite major advances in genetic testing for breast cancer risk prediction, death rates remain disproportionately high among ...

Understanding those genetic “errors” has become central to modern lung cancer care. Biomarker testing, sometimes called ...

Objective To compare the diagnostic accuracy of minipad collected menstrual blood versus clinician collected cervical samples to test for human papillomavirus (HPV) in the detection of cervical ...

Mississippi's House Bill 565, known as Jill's Law, aims to provide coverage for biomarker testing to improve cancer treatment ...